FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma By Ogkologos - May 23, 2025 447 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study AK105-304 and Study AK105-202 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer MOST POPULAR Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with... December 12, 2024 For Advanced Prostate Cancer, Radiopharmaceutical Improves Survival June 29, 2021 Clinical Benefit of a Combination of Ipilimumab and Nivolumab in Treatment-Naïve... April 15, 2025 Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma June 21, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Durvalumab to Include Treatment of... Grabbing the Perfect Gift Addressing Cancer Pain with Complementary Methods (Part 1) PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer
